Where do we stand? Functional imaging in acute and chronic pulmonary embolism with state-of-the-art CT

被引:10
|
作者
Meyer, Mathias [1 ,3 ]
Haubenreisser, Holger [1 ,3 ]
Sudarski, Sonja [1 ,3 ]
Doesch, Christina [2 ,3 ]
Ong, Melissa M. [1 ]
Borggrefe, Martin [2 ,3 ]
Schoenberg, Stefan O. [1 ]
Henzler, Thomas [1 ,3 ]
机构
[1] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Inst Clin Radiol & Nucl Med, D-68167 Mannheim, Germany
[2] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Dept Med 1, D-68167 Mannheim, Germany
[3] DZHK German Ctr Cardiovasc Res Partner Site Mannh, Mannheim, Germany
关键词
Pulmonary embolism; Chronic pulmonary embolism; Computed tomography; Dual-energy; Pulmonary perfusion; Right heart failure; DUAL-ENERGY CT; RIGHT-VENTRICULAR DYSFUNCTION; MULTIDETECTOR COMPUTED-TOMOGRAPHY; PERFUSION DEFECT SCORE; BLOOD-VOLUME IMAGES; SEVERITY ASSESSMENT; ANGIOGRAPHY; LUNG; HYPERTENSION; DIAGNOSIS;
D O I
10.1016/j.ejrad.2015.09.015
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Nowadays, CT pulmonary angiography (CTPA) is the diagnostic imaging modality of choice for acute and chronic pulmonary embolism (PE) in order to assess vascular anatomy and parenchymal morphology. Over the past decade, several prognostic CTPA markers associated with an increased risk of adverse clinical events and in-hospital mortality have been evaluated, namely cardiac chamber dimensions, obstruction scores, and visualization of iodinated contrast material in the lung parenchyma by dual-energy (DE) CTPA. This article reviews the current status and potential prognostic advantages of CTPA or DE CTPA with its recent developments for accessing right ventricular dysfunction and the assessment of first pass lung perfusion with DE CTPA in the diagnosis of acute and chronic PE. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:2432 / 2437
页数:6
相关论文
共 50 条
  • [21] Where do we stand with chronic prostatitis? An update
    Khastgir, J
    Dickinson, AJ
    HOSPITAL MEDICINE, 2003, 64 (12): : 732 - 736
  • [22] Malnutrition: Where Do We Stand in Acute Care?
    Marcason, Wendy
    JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS, 2012, 112 (01) : 200 - 200
  • [23] Where do we stand on solid state microdosimetry?
    Zaider, M
    Dicello, JF
    Horowitz, Y
    RADIATION PROTECTION DOSIMETRY, 1999, 82 (03) : 163 - 166
  • [24] Pulmonary hypertension and beta blockers: where do we stand? Where are we going?
    Bugan, B.
    Roach, E. C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (02) : 229 - 234
  • [25] Tympanostomy Tubes-Where We Were, Where We Are, and Where We Will Be: A State-of-The-Art Review
    de Ru, J. Alexander
    ENT-EAR NOSE & THROAT JOURNAL, 2023, 102 (04) : NP199 - NP200
  • [26] Tympanostomy Tubes-Where We Were, Where We Are, and Where We Will Be: A State-of-the-Art Review
    Dohar, Joseph E.
    Anon, Jack B.
    ENT-EAR NOSE & THROAT JOURNAL, 2020, 99 (1_SUPPL) : 1S - 1S
  • [27] Introduction Chronic Lymphocytic Leukemia. Where Do We Stand, Where Do We Go
    Foa, Robin
    Montserrat, Emili
    CANCER JOURNAL, 2021, 27 (04): : 257 - 258
  • [28] Management of pulmonary embolism: 2010 State-of-the-art update
    Carman T.L.
    Gegaj F.
    Current Treatment Options in Cardiovascular Medicine, 2010, 12 (2) : 168 - 184
  • [29] Hepatotoxicity induced by acute and chronic paracetamol overdose in children: Where do we stand?
    Hoi Yan Tong
    Nicolás Medrano
    Alberto Manuel Borobia
    José Antonio Ruiz
    Ana María Martínez
    Julia Martín
    Manuel Quintana
    Santos García
    Antonio José Carcas
    Elena Ramírez
    World Journal of Pediatrics, 2017, 13 : 76 - 83
  • [30] Hepatotoxicity induced by acute and chronic paracetamol overdose in children: Where do we stand?
    Tong, Hoi Yan
    Medrano, Nicolas
    Borobia, Alberto Manuel
    Ruiz, Jose Antonio
    Martinez, Ana Maria
    Martin, Julia
    Quintana, Manuel
    Garcia, Santos
    Carcas, Antonio Jose
    Ramirez, Elena
    WORLD JOURNAL OF PEDIATRICS, 2017, 13 (01) : 76 - 83